Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Integra Lifesciences Holdings Cash-to-Debt?
Integra Lifesciences HoldingsIART +1.83%70 Cash-to-Debt is 0.13 as of Jun. 2026, which is 19% below its 10-year median of 0.16. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $20.53 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 88.93% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Integra Lifesciences Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.13.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Integra Lifesciences Holdingscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Integra Lifesciences Holdings's Cash-to-Debt or its related term are showing as below:
IART'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1 Med: 0.16 Max: 0.41
Current: 0.13
During the past 13 years, Integra Lifesciences Holdings's highest Cash to Debt Ratio was 0.41. The lowest was 0.10. And the median was 0.16.
IART's Cash-to-Debt is ranked worse than 88.93% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs IART: 0.13
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Integra Lifesciences Holdings Cash-to-Debt Related Terms
Integra Lifesciences Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Integra Lifesciences Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a Cash-to-Debt of 0.13 as of Jun. 2026. This is 19% below median its historical median of 0.16. Over the past decade, Integra Lifesciences Holdings' Cash-to-Debt has ranged from 0.10 to 0.41. According to the industry distribution chart, Integra Lifesciences Holdings ranks #747 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 88.9%.
Is Integra Lifesciences Holdings' Cash-to-Debt too high?
Integra Lifesciences Holdings' current Cash-to-Debt of 0.13 is 19% below median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.41. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Integra Lifesciences Holdings' value of 0.13 is 92% below this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #747 out of 840 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Cash-to-Debt compare to AORT and PRCT?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #747 out of 840 companies for Cash-to-Debt. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Integra Lifesciences Holdings' value of 0.13 is 92% below this benchmark. Historically, Integra Lifesciences Holdings' own Cash-to-Debt has ranged from 0.10 to 0.41 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 1.64, Integra Lifesciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current Cash-to-Debt of 0.13 is 92% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current Cash-to-Debt is 0.13, which is 19% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.53, compared to a current price of $16.72 — trading 18.6% below its estimated fair value. The current Cash-to-Debt is 0.13, which is 19% below median its 10-year median of 0.16 and 92% below the Medical Devices & Instruments industry median of 1.64. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Cash-to-Debt is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $16.72 is trading 18.6% below its estimated GF Value™ of $20.53.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
Cash-to-Debt: 0.13 (19% below median its 10-year median of 0.16)
GF Value™: $20.53 vs. price of $16.72 (18.6% below fair value)
Industry Position: 92% below the Medical Devices & Instruments median (#747 of 840)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
